Search clinical trials for: Moxonidine

Total 20 results

Vanderbilt University Medical Center

Recruiting

Sympathetic Mechanisms in Obesity-Crossover Design

Hypertension | Obesity

United States
Royal Perth Hospital
The University of Western Australia

Recruiting

Sympathoinhibition as a Preferred Second Line Treatment of Obesity Related Hypertension (OHT)

Hypertension | Obesity

Australia
Italo Biaggioni
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

Sympathetic Mechanisms in the Cardiovascular and Metabolic Alterations of Obesity

Obesity-Associated Insulin Resistance

United States
Vanderbilt University Medical Center
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

Autonomic Determinants of POTS - Pilot 2

Postural Tachycardia Syndrome

United States
Vanderbilt University Medical Center
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

Autonomic Determinants of POTS - Pilot1

Postural Tachycardia Syndrome

United States
Baker Heart and Diabetes Institute

Completed

Sympathetic Nervous System Inhibition for the Treatment of Diabetic Kidney Disease

Diabetic Nephropathies

Australia
Royal Perth Hospital

Completed

Role of Sympathetic Activation in Ischemia Reperfusion Injury

Central Sympathetic Nervous System Diseases

Australia
Aristotle University Of Thessaloniki

Completed

Moxonidine Effects on Neuropeptide Y

Hypertension | Obesity
National Research Center for Preventive Medicine

Completed

Comparative Effects of Moxonidine on Bone Metabolism, Vascular and Cellular Aging in Hypertensive Postmenopausal Women (COMPASS)

Osteopenia | Arterial Hypertension

Russian Federation
Sergey V. Nedogoda

Unknown

Moxonidine + Perindopril in Hypertensive Patients With Metabolic Syndrome (COMPOSER)

Metabolic Syndrome | Arterial Hypertension

Russian Federation
Baker Heart and Diabetes Institute
The Alfred; Monash Medical Centre; Ballarat Health Services

Withdrawn

Alleviating the Metabolic Side Effects of Antipsychotic Medications

Schizophrenia

Australia
Baker Heart and Diabetes Institute

Completed

Polycystic Ovary Syndrome - Improving Outcomes

Polycystic Ovary Syndrome

Australia
Spyridon Deftereos

Completed

Moxonidine for Prevention of Post-ablation AFib Recurrences

Atrial Fibrillation

Greece
Baker Heart and Diabetes Institute

Unknown

Study of the Effect of Moxonidine and Diet on Sympathetic Functions in Young Adults With Obesity

Obesity | Overweight

Australia
University of Leeds
The Leeds Teaching Hospitals NHS Trust

Completed

Pathophysiological Mechanisms of Hypertensive LVH:Optimising Regression

Hypertension | Left Ventricular Hypertrophy

United Kingdom
UMC Utrecht
Novartis Pharmaceuticals

Completed

Treatment of Adiposity Related hypErTension (TARGET) (TARGET)

Hypertension | Metabolic Syndrome | Abdominal Obesity

Netherlands
Baker Heart and Diabetes Institute

Unknown

The Effect of Moxonidine on Blood Pressure and Regression of Early Target Organ Damage in Young Subjects With Abdominal Obesity and Hypertension

Hypertension | Abdominal Obesity

Australia
University Hospital, Basel, Switzerland

Terminated

Moxonidine in Patients Undergoing Vascular Surgery

Cardiac Disease | Vascular Surgery

Switzerland
University of Aarhus
Novartis; Danish Heart Foundation; Danish Cardiovascular Research Academy

Terminated

Effects of Intensive Long-Term Vasodilation in Hypertensive Patients With Microvascular Angina Pectoris

Hypertension | Microvascular Angina

Denmark
Solvay Pharmaceuticals

Completed

Efficacy and Safety of Moxonidine in Indian Patients

Hypertension

India

Search clinical trials for: Moxonidine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Macedonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations